Related Experiment Video
Updated: Jun 24, 2026
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach
1City of Hope Comprehensive Cancer Center, Duarte, CA, U.S.A. spal@coh.org
Abstract:
Numerous therapeutic options have been introduced for metastatic renal cell carcinoma (MRCC) in recent years, including monoclonal antibodies such as bevacizumab and small-molecule tyrosine kinase inhibitors such as sunitinib and sorafenib. Similarly, several other small-molecule inhibitors-including imatinib, dasatinib, and nilotinib-have been approved for the treatment of chronic myelogenous leukemia (CML). The combination of these targeted agents is an area of intense clinical investigation. Here, we describe a patient diagnosed with MRCC)while on imatinib therapy for cml. Treatment of this patient with the combination of bevacizumab and imatinib led to a 6-month period of stable disease, with no treatment-related adverse events. More extensive clinical exploration of this combination of agents may therefore be warranted.
Insights
This case study explores combining bevacizumab and imatinib for metastatic renal cell carcinoma (MRCC) in a patient with chronic myelogenous leukemia (CML). The combination showed a 6-month stable disease period with no adverse events, suggesting further investigation is warranted.
Area of Science:
- Oncology
- Pharmacology
Background:
- Recent advancements in metastatic renal cell carcinoma (MRCC) treatments include monoclonal antibodies like bevacizumab and tyrosine kinase inhibitors (TKIs) such as sunitinib and sorafenib.
- Small-molecule TKIs like imatinib, dasatinib, and nilotinib are approved for chronic myelogenous leukemia (CML).
- Investigating combinations of targeted therapies is a key area in clinical research.
Purpose of the Study:
- To report on a patient with MRCC who was concurrently undergoing treatment for CML with imatinib.
- To evaluate the efficacy and safety of combining bevacizumab and imatinib in this patient population.
Main Methods:
- A single patient case report.
- Treatment involved the combination of bevacizumab and imatinib.
- Disease status and adverse events were monitored.
Main Results:
- The patient achieved a 6-month period of stable disease.
- No treatment-related adverse events were observed during the combination therapy.
Conclusions:
- The combination of bevacizumab and imatinib demonstrated potential in managing MRCC in a patient also treated for CML.
- Further clinical trials are recommended to explore this combination therapy more broadly.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...